FDA Approves New Option for Chronic Hives

(MedPage Today) -- The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade, drugmakers Regeneron and Sanofi announced...